Foster-Cheek Kaye I 4
4 · AGIOS PHARMACEUTICALS, INC. · Filed Jun 23, 2025
Insider Transaction Report
Form 4
Foster-Cheek Kaye I
Director
Transactions
- Exercise/Conversion
Common stock
2025-06-20+2,120→ 7,468 total - Exercise/Conversion
Restricted stock units
2025-06-20−2,120→ 0 total→ Common stock (2,120 underlying) - Award
Restricted stock units
2025-06-18+2,816→ 2,816 total→ Common stock (2,816 underlying) - Award
Stock options (right to buy)
2025-06-18+15,768→ 15,768 totalExercise: $35.50Exp: 2035-06-18→ Common stock (15,768 underlying)
Holdings
- 2,200(indirect: By Trust)
Common stock
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- [F2]The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
- [F3]These options were granted on June 18, 2025. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2026.
- [F4]The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested.